Roadmap of miR-122-related clinical application from bench to bedside

Expert Opinion on Investigational Drugs

Volumn 23, Issue 3, 2014, Pages 347-355

  Qiu, Zhihua ^a   Dai, Yimin ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Hepatic diseases; Hepatitis C virus; MicroRNA; MiR 122; Miravirsen

Indexed keywords

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; HUMANS; LIVER DISEASES; MICRORNAS; OLIGONUCLEOTIDES;

EID: 84894090622     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.867327     Document Type: Review

References (93)

1. Bhalala OG, Srikanth M, Kessler JA. The emerging roles of microRNAs in CNS injuries. Nat Rev Neurol 2013;9(6):328-39
2. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013;495:384-8
3. Tardito D, Mallei A, Popoli M. Lost in translation. New unexplored avenues for neuropsychopharmacology: Epigenetics and microRNAs. Expert Opin Investig Drugs 2013;22:217-33
4. Henry JC, Azevedo-Pouly AC, Schmittgen TD. MicroRNA replacement therapy for cancer. Pharm Res 2011;28:3030-42
5. Nikaki A, Piperi C, Papavassiliou AG. Role of microRNAs in gliomagenesis: Targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs 2012;21:1475-88
6. Krutzfeldt J, Poy MN, Stoffel M. Strategies to determine the biological function of microRNAs. Nat Genet 2006;38(Suppl):S14-19
7. Harraz MM, Eacker SM, Wang X, et al. MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proc Natl Acad Sci USA 2012;109:18962-7
8. Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007;100:1579-88
9. Gehrau RC, Mas VR, Maluf DG. Hepatic disease biomarkers and liver transplantation: What is the potential utility of microRNAs? Expert Rev Gastroenterol Hepatol 2013;7:157-70
10. Dassow H, Aigner A. MicroRNAs (miRNAs) in colorectal cancer: From aberrant expression towards therapy. Curr Pharm Des 2013;19:1242-52
11. Li Y, Liu Y, Wang Z, et al. MicroRNA: Not far from clinical application in ischemic stroke. ISRN Stroke 2013;2013:1-7
12. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685-94
13. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54
14. Dai Y, Qiu Z, Diao Z, et al. MicroRNA-155 inhibits proliferation and migration of human extravillous trophoblast derived HTR-8/SVneo cells via down-regulating cyclin D1. Placenta 2012;33:824-9
15. Carlsbecker A, Lee JY, Roberts CJ, et al. Cell signalling by microRNA165/ 6 directs gene dose-dependent root cell fate. Nature 2010;465:316-21
16. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: Tying it all together. Int J Biochem Cell Biol 2009;41:87-95
17. Chitwood DH, Nogueira FT, Howell MD, et al. Pattern formation via small RNA mobility. Genes Dev 2009;23:549-54
18. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006
19. Lee I, Ajay SS, Yook JI, et al. New class of microRNA targets containing simultaneous 5¢-UTR and 3¢-UTR interaction sites. Genome Res 2009;19:1175-83
20. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004;1:106-13
21. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12:735-9
22. Sempere LF, Freemantle S, Pitha-Rowe I, et al. Expression profiling of mammalian microRNAs uncovers a subset of brainexpressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004;5:R13
23. Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309:1577-81
24. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-9
25. Jiang Y, Zhu J, Xu G, et al. Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv 2011;8:623-32
26. Jiang Y, Wei N, Lu T, et al. Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 2011;172:398-405
27. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-9
28. Girard M, Jacquemin E, Munnich A, et al. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008;48:648-56
29. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198-201
30. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-9
31. Drenth JP. HCV treatment-no more room for interferonologists? N Engl J Med 2013;368:1931-2
32. Jacobson I, Gordon S, Kowdley K, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77
33. Pang PS, Pham EA, Elazar M, et al. Structural map of a microRNA-122: Hepatitis C virus complex. J Virol 2012;86:1250-4
34. Narbus CM, Israelow B, Sourisseau M, et al. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol 2011;85:12087-92
35. Chang J, Guo JT, Jiang D, et al. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol 2008;82:8215-23
36. Fukuhara T, Kambara H, Shiokawa M, et al. Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J Virol 2012;86:7918-33
37. Zellner E, Herrmann T, Schulz C, et al. Site-specific interaction of the murine pre-replicative complex with origin DNA: Assembly and disassembly during cell cycle transit and differentiation. Nucleic Acids Res 2007;35:6701-13
38. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 2010;84:6615-25
39. Shimakami T, Yamane D, Jangra RK, et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci USA 2012;109:941-6
40. Zhang C, Huys A, Thibault PA, et al. Requirements for human Dicer and TRBP in microRNA-122 regulation of HCV translation and RNA abundance. Virology 2012;433:479-88
41. Wilson JA, Huys A. miR-122 Promotion of the hepatitis C virus life cycle: Sound in the silence. Wiley Interdiscip Rev RNA 2013;4(6):665-76
42. Norman KL, Sarnow P. Hepatitis C virus' Achilles' heel-dependence on liverspecific microRNA miR-122. Cell Res 2010;20:247-9
43. Haussecker D, Kay MA. miR-122 continues to blaze the trail for microRNA therapeutics. Mol Ther 2010;18:240-2
44. Hou W, Bukong TN, Kodys K, et al. Alcohol facilitates HCV RNA replication via up-regulation of miR-122 expression and inhibition of cyclin G1 in human hepatoma cells. Alcohol Clin Exp Res 2013;37:599-608
45. Zhao L, Li F, Taylor EW. Can tobacco use promote HCV-induced miR-122 hijacking and hepatocarcinogenesis? Med Hypotheses 2013;80:131-3
46. Li S, Xing X, Yang Q, et al. The effects of hepatitis C virus core protein on the expression of miR-122 in vitro. Virol J 2013;10:98
47. Qiu L, Fan H, Jin W, et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010;398:771-7
48. Hao J, Jin W, Li X, et al. Inhibition of alpha interferon (IFN-Alpha)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-Alpha. J Virol 2013;87:137-47
49. Chen Y, Shen A, Rider PJ, et al. A liverspecific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 2011;25:4511-21
50. Wang S, Qiu L, Yan X, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology 2012;55:730-41
51. Yoshioka W, Higashiyama W, Tohyama C. Involvement of microRNAs in dioxin-induced liver damage in the mouse. Toxicol Sci 2011;122:457-65
52. Tryndyak VP, Latendresse JR, Montgomery B, et al. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a cholineand folate-deficient diet. Toxicol Appl Pharmacol 2012;262:52-9
53. Starckx S, Batheja A, Verheyen GR, et al. Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats. Toxicol Pathol 2013;41:795-804
54. Varnholt H, Drebber U, Schulze F, et al. MicroRNA gene expression profile of hepatitis C virus-Associated hepatocellular carcinoma. Hepatology 2008;47:1223-32
55. Bai S, Nasser MW, Wang B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009;284:32015-27
56. Ma L, Liu J, Shen J, et al. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther 2010;9:554-61
57. Lin CJ, Gong HY, Tseng HC, et al. miR-122 targets an anti-Apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2008;375:315-20
58. Yang F, Zhang L, Wang F, et al. Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma. Neoplasia 2011;13:590-600
59. Jung CJ, Iyengar S, Blahnik KR, et al. Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. PLoS One 2011;6:e27740
60. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98
61. Joven J, Espinel E, Rull A, et al. Plant-derived polyphenols regulate expression of miRNA paralogs miR-103/ 107 and miR-122 and prevent dietinduced fatty liver disease in hyperlipidemic mice. Biochim Biophys Acta 2012;1820:894-9
62. Wen J, Friedman Jr. miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest 2012;122:2773-6
63. Sarasin-Filipowicz M, Krol J, Markiewicz I, et al. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009;15:31-3
64. Morita K, Taketomi A, Shirabe K, et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 2011;31:474-84
65. Cermelli S, Ruggieri A, Marrero JA, et al. Circulating microRNAs in patients with chronic hepatitis C and nonalcoholic fatty liver disease. PLoS One 2011;6:e23937
66. Bihrer V, Friedrich-Rust M, Kronenberger B, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011;106:1663-9
67. Su TH, Liu CH, Liu CJ, et al. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci USA 2013;110:7844-9
68. Koberle V, Waidmann O, Kronenberger B, et al. Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy. J Viral Hepat 2013;20:530-5
69. Ji F, Yang B, Peng X, et al. Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepat 2011;18:e242-51
70. Waidmann O, Bihrer V, Pleli T, et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 2012;19:e58-65
71. Zhang H, Li QY, Guo ZZ, et al. Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World J Gastroenterol 2012;18:5188-96
72. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42
73. Karakatsanis A, Papaconstantinou I, Gazouli M, et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013;52:297-303
74. Koberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013;49(16):3442-9
75. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009;106:4402-7
76. Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009;55:1977-83
77. Starkey Lewis PJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011;54:1767-76
78. Ding X, Ding J, Ning J, et al. Circulating microRNA-122 as a potential biomarker for liver injury. Mol Med Rep 2012;5:1428-32
79. Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminopheninduced acute liver injury at first presentation to hospital. Hepatology 2013;58:777-87
80. Farid WR, Pan Q, van der Meer AJ, et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl 2012;18:290-7
81. Waidmann O, Koberle V, Brunner F, et al. Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One 2012;7:e45652
82. Izzotti A, Calin GA, Arrigo P, et al. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J 2009;23:806-12
83. Hildebrandt-Eriksen ES, Bagger YZ, TB K. A unique therapy for HCV inhibits microRNA-122 in humans and results in HCV RNA suppression in chronically infected chimpanzees: Results from primate and first-in-human studies. Hepatology 2009;50:228A
84. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303
85. Chen Y, Wang C, Liu Y, et al. miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn's disease. Biochem Biophys Res Commun 2013;438:133-9
86. Donaldson A, Natanek SA, Lewis A, et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax 2013;68(12):1140-9
87. Baselga-Escudero L, Arola-Arnal A, Pascual-Serrano A, et al. Chronic Administration of Proanthocyanidins or Docosahexaenoic Acid Reverses the Increase of miR-33a and miR-122 in Dyslipidemic Obese Rats. PLoS One 2013;8:e69817
88. Thomas M, Deiters A. MicroRNA miR-122 as a therapeutic target for oligonucleotides and small molecules. Curr Med Chem 2013;20:3629-40
89. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7
90. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: The end of the beginning. Nat Rev Neurosci 2002;3:824-8
91. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005;64:94-101
92. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 2002;1:3
93. Li Y, Liu Y, Wang Z, et al. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: End of beginning or beginning of end? Expert Opin Biol Ther 2013;13:1515-22